.
.

Continuing Education Activities

Here at JADPRO CE, you can find a valuable array of certified educational opportunities: it’s the place to get your credits and update your learning in oncology. We provide advanced practitioners like you with a wide range of continuing education, covering the most current topics in several formats so you can choose the way you want to learn. You'll find that our CE offerings are easy to navigate. You can sort by topic and/or format, or simply browse the site and get started!

Topic

Format

      Quick Tips →

*Sorted by program start date
CAR T-Cell Therapy
VIDEO

CAR T-Cell Therapy and the Pharmacology of Managing Cytokine Release Syndrome

Learn from two experts on how to identify patients who meet criteria as candidates for CAR T-cell therapy and apply strategies to mitigate associated serious side effects, including cytokine release syndrome.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Indolent Lymphomas
VIDEO

Sequencing Therapies in Indolent Lymphomas (FL and CLL)

Discover current best practices for treating follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL), including monitoring patients with CLL for 17p deletion at diagnosis and throughout the course of the disease and current and emerging data supporting combination therapies in CLL and novel targeted therapies for newly diagnosed and relapsed/refractory FL.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Prostate Cancer
VIDEO

Therapeutic Advances in Prostate Cancer

Learn from two experts in the field of prostate cancer as they discuss clinical data of emerging and current agents for the treatment of non-metastatic castration-resistant prostate cancer for rapidly rising prostate-specific antigen levels, the role of docetaxel and abiraterone in newly diagnosed metastatic disease, emerging data on the role of genomics in metastatic castration-sensitive and -resistant disease, and strategies to manage toxicities of current and emerging treatments.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Hodgkin Lymphoma
VIDEO

Evolving Strategies to Manage Treatment-Related Adverse Events for Patients with Classical Hodgkin Lymphoma

Discover how to prevent and mitigate adverse events of established and emerging cytotoxic regimens, novel agents, and checkpoint inhibitors used to treat classical Hodgkin lymphoma, including best practices and emerging data.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Myeloid Malignancies
VIDEO

New Directions in Myeloid Malignancies

Review strategies to monitor minimal residual disease in myeloid malignancies, as well as the safety and efficacy of novel treatment approaches and associated mutations such as IDH2, TP53, FLT3, BCL2, and cell surface antigen CD33.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Ovarian Cancer
VIDEO

Sequencing of Treatments for Patients With Ovarian Cancer

Take a deep dive into the history of ovarian cancer treatment, evaluate current options for first-line and maintenance therapy, and review safety and efficacy data for PARP inhibitors alone and in combination with immunotherapy or anti-angiogenic agents.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Drug Updates - Heme
VIDEO

New Drug Updates in Hematologic Malignancies

Discover the latest pharmacology and indication approvals for the management of patients with hematologic malignancies, including pivotal clinical trial data, associated signs and symptoms of serious or life-threatening adverse effects, and the impact of these agents in advanced practice.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

DDx Hematologic
VIDEO

Differential Diagnosis and Testing for Hematologic Malignancies

With the backdrop of three unique, real-life case studies, learn how to interpret advancements in diagnostic tests used in risk stratification for hematologic malignancies, including next-generation sequencing for the discovery of novel molecular abnormalities as defined by the World Health Organization and European Leukemia Network.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Plasma Cell Dyscrasias
VIDEO

Advancing the Management of Plasma Cell Dyscrasias

Through expert, case-based discussion, learn how to interpret differential diagnoses of plasma cell dyscrasias, implement the recent changes in the clinical management of the spectrum of multiple myeloma, evaluate the risks and benefits of early treatments for smoldering myeloma, and plan management strategies for patients with solitary plasmacytomas and amyloidosis.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Thoracic Cancer
VIDEO

Management of Side Effects for Patients Receiving Multimodality Therapy in Thoracic Oncology

Discover strategies to mitigate adverse events (AEs) of checkpoint inhibitors and radiotherapy for patients with thoracic cancer, and review emerging data regarding managing AEs of EGFR and ALK inhibitors.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Drug Updates - Solid
VIDEO

New Drug Updates in Solid Tumors

Review the pharmacology and approved indications of medications for the management of solid tumors, including pivotal clinical trial data, the signs and symptoms of associated serious or life-threatening adverse effects, and each drug’s impact on advanced practice.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Melanoma
VIDEO

Evolving Therapies in the Clinical Management of Melanoma

Take a deep dive into clinical data supporting immunotherapies and emerging targeted therapies for the treatment of advanced/metastatic melanoma, as well as strategies to manage and mitigate associated adverse events.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

VTE Prevention
VIDEO

Preventing and Treating Venous Thrombosis in Oncology

Discover how to interpret recent findings comparing safety and efficacy of “standard” anticoagulants with those of direct oral anticoagulants (DOACs), evaluate the risks and benefits of treatment of DOACs, and monitor and assess patient response to anticoagulant treatment.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

RCC
VIDEO

Sequencing Therapies in Renal Cell Carcinoma

Review strategies for how to best utilize immunotherapy in renal cell carcinoma, including tyrosine kinase inhibitors in the adjuvant setting in patients with advanced disease.

Posted: 1/31/2019 / Expires: 1/31/2020

Estimated time to complete: 1 hour

Hematologic Malignancies
FDA
Side Effect Management
Risk Stratification
Novel Therapy
CAR T-Cell Therapy
VIDEO

Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents

This presentation reviews current treatments for early-stage and relapsed/refractory diffuse large B-cell lymphoma and mantle cell lymphoma. Emerging therapies, including CAR T-cell therapy, along with patient selection criteria and toxicities unique to new treatments are addressed as well.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 1 hour and 30 minutes

Hematologic Malignancies
Cell Signaling Pathways
CLL
Side Effect Management
Risk Stratification
Novel Therapy
Lymphomas and Leukemias
VIDEO

Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents

Dive into current strategies for managing patients with chronic lymphocytic leukemia and follicular lymphoma, including the risk-adapted treatment selection of new therapies based on factors such as patient age, performance status, and comorbidities. The latest data on the efficacy and safety of newly approved agents are presented, and strategies to treat common side effects reviewed.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 1 hour

Hematologic Malignancies
Checkpoint Inhibition
FDA
Multiple Myeloma
Side Effect Management
Risk Stratification
Novel Therapy
VIDEO

Emerging Therapies for Multiple Myeloma

The overall survival of patients with multiple myeloma has increased within the past decade, thanks to newer agents such as immunomodulatory drugs and proteasome inhibitors. Receive updated data on key FDA approvals and practice updates for maximizing therapies while mitigating adverse events.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 45 minutes

Hematologic Malignancies
Checkpoint Inhibition
FDA
irAEs
Side Effect Management
Risk Stratification
Novel Therapy
VIDEO

Emerging Therapies for Hodgkin Lymphoma

In this lecture, learn about the principles of treatment for relapsed/refractory classical Hodgkin lymphoma, including therapeutic targets and mechanisms of action of newly approved agents in order to educate and manage patients effectively. Hear from an expert in the field on best practices for treating immune-related adverse events such as pneumonitis, hyperthyroidism, and colitis.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 30 minutes

Hematologic Malignancies
Checkpoint Inhibition
FDA
MPN
Side Effect Management
Risk Stratification
Novel Therapy
VIDEO

Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms

Get an overview of the diagnostic criteria and key clinical trials for Philadelphia chromosome–negative classical myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. Learn about the role of the JAK-STAT signaling pathway, as well as strategies for optimizing the selection and sequencing of treatments for patients with myeloproliferative neoplasms.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 1 hour

Hematologic Malignancies
AML
Cell Signaling Pathways
Checkpoint Inhibition
FDA
Side Effect Management
Risk Stratification
Novel Therapy
Lymphomas and Leukemias
VIDEO

Risk-Adapted Treatment of Acute Myelogenous Leukemia

Acute myeloid leukemia is a heterogenous group of distinct malignancies that accounts for 80% of acute leukemias in adults. Recent advancements in diagnostic tests, such as next-generation sequencing, have led to the identification of unique biomarkers associated with acute myeloid leukemia. These advancements, along with new targeted therapies, offer hope for a greater impact of survival for patients with this disease.

Posted: 7/16/2018 / Expires: 7/16/2019

Estimated time to complete: 1 hour and 15 minutes

Immunotherapy
Adjuvant Treatment
Checkpoint Inhibition
FDA
PD1
PDL1
irAEs
Side Effect Management
Novel Therapy
VIDEO

Overview of the Immune System and Immune Checkpoint Targets and Their Mechanisms of Action

This lecture provides a comprehensive overview of the immune system and current immunotherapeutic strategies, including discussions on the difference between innate and adaptive immunity, significance of neoantigens, and emerging checkpoint inhibitors.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 45 minutes

Immunotherapy
Checkpoint Inhibition
Next Generation Sequencing
PD1
PDL1
Side Effect Management
Novel Therapy
VIDEO

Immunotherapy: Treatment-Related Issues

There are several treatment-related issues that advanced practitioners caring for patients with cancer should be aware of. Factors predictive of response to immunotherapy, different combinations of treatments, and immunotherapy response patterns are reviewed.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 45 minutes

Immunotherapy
Adjuvant Treatment
Checkpoint Inhibition
Diarrhea
FDA
PD1
PDL1
irAEs
Side Effect Management
Novel Therapy
VIDEO

Immune-Related Adverse Events

Immunotherapy has been the source of promising new cancer treatments, but carries with it a host of side effects that can affect any organ system. The range of possible side effects makes it important for advanced practitioners to understand the timing and incidence of immune-related adverse events, as well as to recognize and manage these adverse events for patients to receive the full benefit of their treatment.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 1 hour

Immunotherapy
Adjuvant Treatment
Checkpoint Inhibition
Diarrhea
FDA
irAEs
RCC
Side Effect Management
Risk Stratification
Novel Therapy
VIDEO

Renal Cell Carcinoma

40% of patients develop metastasis after primary surgical resection of localized renal cell carcinoma (RCC); this signifies an unmet need for the treatment of metastatic RCC. The mainstay of treatment has been antiangiogenic agents for previously untreated patients, and nivolumab has been shown to improve survival for patients who received prior antiangiogenic therapy. Details on the clinical trial upon which FDA approval for nivolumab was based on, as well as a case study illustrating how to appropriately manage immune-related dermatitis and arthritis are discussed in this video.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 30 minutes

Immunotherapy
ALK Positive NSCLC
Checkpoint Inhibition
EGFR
FDA
PD1
PDL1
irAEs
NSCLC
Side Effect Management
Novel Therapy
Lung Cancer
VIDEO

Non-Small Cell Lung Cancer

The role of immunotherapy in non–small cell lung cancer has been rapidly expanding as results from several clinical trials have come out in recent years. Takeaways from these studies and a differential diagnosis of a case study patient with anemia and nephritis demonstrate key points advanced practitioners should be aware of when managing this patient population.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 45 minutes

Immunotherapy
Adjuvant Treatment
Checkpoint Inhibition
Diarrhea
FDA
PD1
PDL1
irAEs
Melanoma
Side Effect Management
Novel Therapy
VIDEO

Melanoma

Melanoma is one of the few malignancies where the incidence is on the rise. In this case-based lecture, approved immunotherapies for the treatment of patients with melanoma are discussed, and a case study of a patient with stage IV melanoma complaining of fever, cough, and shortness of breath is presented.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 30 minutes

Immunotherapy
Checkpoint Inhibition
Diarrhea
FDA
Next Generation Sequencing
PD1
PDL1
irAEs
MSI-H
Side Effect Management
Novel Therapy
VIDEO

Mismatch Repair Deficient (dMMR) and Microsatellite Instability-High (MSI-H) Tumors

The use of immune checkpoint inhibitors is emerging as an effective strategy to treat patients with mismatch repair–deficient and microsatellite instability–high tumors. This presentation summarizes data on currently available immunotherapeutic agents for these tumors and details the appropriate management of immune-related hypothyroidism.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 30 minutes

Immunotherapy
Adjuvant Treatment
Bladder Cancer
Checkpoint Inhibition
Diarrhea
FDA
irAEs
Side Effect Management
Novel Therapy
VIDEO

Metastatic Urothelial Carcinoma

After decades of no new approvals for the treatment of metastatic urothelial cancer, a malignancy associated with a low survival rate, novel immunotherapeutic agents are changing the treatment landscape for bladder cancer. Learn about the therapies showing activity in this malignancy and get clinical pearls on how to manage a patient with urothelial cancer with immune-related hepatitis and pancreatitis.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 30 minutes

Immunotherapy
Adjuvant Treatment
Checkpoint Inhibition
EGFR
FDA
irAEs
SCCHN
Side Effect Management
Novel Therapy
VIDEO

Head and Neck Cancer

Data on currently available immunotherapeutic agents for recurrent/metastatic head and neck squamous cell carcinoma point to a new standard of care with immune checkpoint inhibitors. Listen to the latest results comparing these inhibitors to chemotherapy, and the symptoms, workup, diagnosis, and management of a head and neck squamous cell carcinoma patient with hypophysitis.

Posted: 6/28/2018 / Expires: 6/28/2019

Estimated time to complete: 30 minutes

Hodgkin Lymphoma
PODCAST

Role of Antibody-Drug Conjugates for Front-Line Therapy in Classical Hodgkin Lymphoma

Amy Goodrich, RN, MSN, CRNP-AC, and Nadia Khan, MD, discuss the role of antibody-drug conjugates in the treatment of classical Hodgkin lymphoma, including mechanism of action, recent approvals, emerging data, and expert guidance on clinical application.

Posted: 2/28/2019 / Expires: 2/28/2020

Estimated time to complete: 30 minutes

Hodgkin Lymphoma
PODCAST

Anticipating and Managing Side Effects for Patients With Classical Hodgkin Lymphoma

Amy Goodrich, RN, MSN, CRNP-AC, and Barbara Rogers, CRNP, MN, AOCN®, ANP-BC, review best practices for anticipating and managing side effects for patients being treated for classical Hodgkin lymphoma, including the short- and long-term adverse events associated with chemotherapy, checkpoint inhibitors, and antibody–drug conjugates.

Posted: 2/28/2019 / Expires: 2/28/2020

Estimated time to complete: 30 minutes

Hodgkin Lymphoma
PODCAST

Shared Decision-Making: How to Discuss Therapeutic Options With Your Patients Considering Treatment for Classical Hodgkin Lymphoma

Amy Goodrich, RN, MSN, CRNP-AC, and Kevin Nguyen, a patient who was treated for classical Hodgkin lymphoma, discuss his treatment journey from diagnosis through relapse and how shared decision-making between him and his health-care team played an important role in the process.

Posted: 2/28/2019 / Expires: 2/28/2020

Estimated time to complete: 30 minutes

Melanoma
Print

Understanding the Role of Targets and Pathways in the Treatment of Melanoma

Incidence rates of melanoma continue to climb, and while most patients are diagnosed at an early stage, once metastatic, melanoma remains the most deadly of all the cutaneous malignancies. With the discovery of immune checkpoints and therapies that target the MAPK pathway, patients with metastatic melanoma have new treatment options and renewed hope.

Posted: 11/27/2018 / Expires: 11/27/2019

Estimated time to complete: 3 hours

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.